Building on this approval, we designed a prospective trial to explore the efficacy and tolerability of combining sintilimab with anlotinib in patients whose NSCLC advanced after first‐line PD‐(L)1 antibody therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.